Menu
 
Research menu
Jump to menu

Publications:  Dr Gareth Pryce

Baker D, Pryce G, Herrod SS, Schmierer K(2019). Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord vol. 30, 176-186.
10.1016/j.msard.2019.02.018
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55609
BAKER D, GIOVANNONI G, PRYCE G, AMOR S, SCHMIERER K(2018). Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. Brain
10.1093/brain/awy239
https://qmro.qmul.ac.uk/xmlui/handle/123456789/45063
BO X, GUSHCHINA S, PRYCE G, YIP P, Wu D, PALLIER P, GIOVANNONI G, BAKER D(2018). Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss. Glia
10.1002/glia.23464
https://qmro.qmul.ac.uk/xmlui/handle/123456789/43866
BO XUENONG, GUSHCHINA S, PRYCE G, YIP P, WU D, PALLIER P, GIOVANNONI G, BAKER D(2018). Increased expression of colony‐stimulating factor‐1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss. Glia vol. 66, (10) 2108-2125.
10.1002/glia.23464
https://qmro.qmul.ac.uk/xmlui/handle/123456789/43866
BAKER D, Pryce, G(2018). Oligoclonal bands in multiple sclerosis; functional significance and therapeutic implications. Does the specificity matter?. multiple sclerosis and related disorders
10.1016/j.msard.2018.07.03
https://qmro.qmul.ac.uk/xmlui/handle/123456789/43565
Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S et al.(2018). Alemtuzumab depletion failure can occur in multiple sclerosis. Immunology vol. 154, (2) 253-260.
10.1111/imm.12879
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31849
Pryce G, Baker D(2017). Antidote to cannabinoid intoxication: the CB1 receptor inverse agonist, AM251, reverses hypothermic effects of the CB1 receptor agonist, CB-13, in mice. Br J Pharmacol vol. 174, (21) 3790-3794.
10.1111/bph.13973
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25739
BAKER D(2017). Big conductance calcium-activated potassium channel openers control spasticity without sedation. British Journal of Pharmcology
10.1111/bph.13889
https://qmro.qmul.ac.uk/xmlui/handle/123456789/53704
von Kutzleben S, Pryce G, Giovannoni G, Baker D(2017). Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis. Immunology vol. 150, (4) 444-455.
10.1111/imm.12696
https://qmro.qmul.ac.uk/xmlui/handle/123456789/19408
Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K(2017). Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine vol. 16, 41-50.
10.1016/j.ebiom.2017.01.042
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23134
Williams T, Pryce G, Giovannoni G, Selwood D, Baker D (2016). VSN16R-A NOVEL TREATMENT FOR SPASTICITY IN EXPERIMENTAL MULTIPLE SCLEROSIS. vol. 87, is. 12, Abstract: java.sql.Clob org.hibernate.engine.jdbc.WrappedClob java.io.Serializable ,
10.1136/jnnp-2016-315106.162
https://qmro.qmul.ac.uk/xmlui/handle/123456789/29783
Peferoen LAN, Breur M, van de Berg S, Peferoen-Baert R, Boddeke EHWGM, van der Valk P, Pryce G, van Noort JM et al.(2016). Ageing and recurrent episodes of neuroinflammation promote progressive experimental autoimmune encephalomyelitis in Biozzi ABH mice. Immunology vol. 149, (2) 146-156.
10.1111/imm.12644
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13480
Sevastou I, Pryce G, Baker D, Selwood DL(2016). Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing. PLOS ONE vol. 11, (6) e0157754-e0157754.
10.1371/journal.pone.0157754
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13513
Ummenthum K, Peferoen LAN, Finardi A, Baker D, Pryce G, Mantovani A, Bsibsi M, Bottazzi B et al.(2016). Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease. Eur J Immunol vol. 46, (3) 701-711.
10.1002/eji.201545950
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13679
Warne J, Pryce G, Hill JM, Shi X, Lennerås F, Puentes F, Kip M, Hilditch L et al.(2016). Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis. J Biol Chem vol. 291, (9) 4356-4373.
10.1074/jbc.M115.700385
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11312
Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D(2015). Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. Journal of Neuroimmune Pharmacology vol. 10, (2) 281-292.
10.1007/s11481-014-9575-8
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11925
Pryce G, Baker D(2015). Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis. Evid Based Med vol. 20, (4)
10.1136/ebmed-2015-110198
Vainchtein I, Vinet J, Al-Izki S, Pryce G, Grit C, Brouwer N, Amor S, Baker D et al. (2015). Microglia are involved in apoptotic clearance during chronic-relapsing EAE. GLIA. vol. 63, E353-E353.
Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D(2015). Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. J Neuroimmune Pharmacol vol. 10, (2) 281-292.
10.1007/s11481-014-9575-8
Wu D, Cerutti C, Lopez-Ramirez MA, Pryce G, King-Robson J, Simpson JE, van der Pol SM, Hirst MC et al.(2015). Brain endothelial miR-146a negatively modulates T-cell adhesion through repressing multiple targets to inhibit NF-κB activation. J Cereb Blood Flow Metab vol. 35, (3) 412-423.
10.1038/jcbfm.2014.207
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9649
Pryce G, Baker D(2015). Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis. Handb Exp Pharmacol vol. 231, 213-231.
10.1007/978-3-319-20825-1_7
Von Kutzleben S, Pryce G, Chretien N, Turner M, Siders W, Baker D (2014). Inhibition of relapsing experimental autoimmune encephalomyelitis in Biozzi ABH mice using a mouse CD52-specific monoclonal antibody. JOURNAL OF NEUROIMMUNOLOGY. vol. 275, 228-228.
10.1016/j.jneuroim.2014.08.611
Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, Kay O, de Vries HE et al.(2014). MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation. FASEB J vol. 28, (6) 2551-2565.
10.1096/fj.13-248880
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7990
Pryce G, Visintin C, Ramagopalan SV, Al-Izki S, De Faveri LE, Nuamah RA, Mein CA, Montpetit A et al.(2014). Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists. FASEB J vol. 28, (1) 117-130.
10.1096/fj.13-239442
Mullen L, Rigby A, Sclanders M, Adams G, Mittal G, Colston J, Fatah R, Subang C et al.(2014). Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. Expert Opin Drug Deliv vol. 11, (1) 5-16.
10.1517/17425247.2013.839655
Al-Izki S, Pryce G, Hankey DJR, Lidster K, von Kutzleben SM, Browne L, Clutterbuck L, Posada C et al.(2014). Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. Brain vol. 137, (Pt 1) 92-108.
10.1093/brain/awt324
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9650
Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin RJ, Giovannoni G, Baker D, Chandran S(2013). Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathol Commun vol. 1,
10.1186/2051-5960-1-84
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18967
Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long JZ, Cravatt BF, Giovannoni G et al.(2013). Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. Mult Scler vol. 19, (14) 1896-1904.
10.1177/1352458513485982
Puentes F, van der Star BJ, Victor M, Kipp M, Beyer C, Peferoen-Baert R, Ummenthum K, Pryce G et al.(2013). Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation vol. 10,
10.1186/1742-2094-10-118
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7824
Baker D, Lidster K, Al-Izki S, Pryce G, Giovannoni G(2013). Animal models of progressive disability in MS. IRISH JOURNAL OF MEDICAL SCIENCE vol. 182, S5-S6.
Sisay S, Pryce G, Jackson SJ, Tanner C, Ross RA, Michael GJ, Selwood DL, Giovannoni G et al.(2013). Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis. PLoS One vol. 8, (10)
10.1371/journal.pone.0076907
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6281
Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, de Vries HE, Hirst MC et al. (2012). Endothelial miR-155 promotes blood brain barrier dysfunction in neuroinflammation. JOURNAL OF NEUROIMMUNOLOGY. vol. 253, 3-4.
Pryce G, Baker D(2012). Potential control of multiple sclerosis by cannabis and the endocannabinoid system. CNS Neurol Disord Drug Targets vol. 11, (5) 624-641.
10.2174/187152712801661310
Gnanapavan S, Grant D, Pryce G, Jackson S, Baker D, Giovannoni G(2012). Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis. Autoimmunity vol. 45, (4) 298-303.
10.3109/08916934.2012.654865
Baker D, Pryce G, Jackson SJ, Bolton C, Giovannoni G(2012). The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Mult Scler Relat Disord vol. 1, (2) 64-75.
10.1016/j.msard.2011.11.001
Hilliard A, Stott C, Wright S, Guy G, Pryce G, Al-Izki S, Bolton C, Giovannoni G(2012). Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis. ISRN Neurol vol. 2012,
10.5402/2012/802649
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18983
Al-Izki S, Pryce G, O'Neill JK, Butter C, Giovannoni G, Amor S, Baker D(2012). Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Mult Scler Relat Disord vol. 1, (1) 29-38.
10.1016/j.msard.2011.09.001
Graves RS, Pryce G, Cabranes A, Fernandez-Ruiz J, Bisogno T, Di Marzo V, Cravatt BF, Michael GJ et al.(2011). Fatty acid amide hydrolase as a target for neuroprotection. MULTIPLE SCLEROSIS JOURNAL vol. 17, S431-S431.
Al-Izki S, Pryce G, Amor S, Gerritsen W, Garthwaite J, Giovannoni G, Selwood DL, Baker D(2011). Selective targeting of neuroprotection to MS lesions: sodium channel blockers in experimental autoimmune encephalomyelitis. MULTIPLE SCLEROSIS JOURNAL vol. 17, S209-S210.
Pryce G, Visintin C, Lutz B, Marsicano G, Giovannoni G, Selwood DL, Baker D(2011). Selective targeting of spasticity by CNS-excluded cannabinoids. MULTIPLE SCLEROSIS JOURNAL vol. 17, S247-S247.
Baker D, Pryce G, Visintin C, Pertwee RG, Tanner C, Ross R, Irving A, Sisay S et al.(2011). VSN16R a novel agent for the control of spasticity. MULTIPLE SCLEROSIS JOURNAL vol. 17, S243-S243.
Ayoub SS, Pryce G, Seed MP, Bolton C, Flower RJ, Baker D(2011). Paracetamol-induced hypothermia is independent of cannabinoids and transient receptor potential vanilloid-1 and is not mediated by AM404. Drug Metab Dispos vol. 39, (9) 1689-1695.
10.1124/dmd.111.038638
Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D(2011). Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult Scler vol. 17, (8) 939-948.
10.1177/1352458511400476
Al-Izki S, Pryce G, Giovannoni G, Baker D(2009). Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography. Mult Scler vol. 15, (7) 795-801.
10.1177/1352458509104594
Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, Compston A, Franklin RJM et al.(2008). An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J NEUROIMMUNOL vol. 201, 200-211.
10.1016/j.jneuroim.2008.05.034
Jackson S, Al-Izik S, Pryce G, Giovannoni G, Baker D (2008). Fingolimod reduces axonal loss in relapsing secondary progressive experimental autoimmune encephalomyelitis. MULTIPLE SCLEROSIS. vol. 14, S80-S81.
Parkes H, Shorter S, So PW, Baker D, Pryce G, Giovannoni G, Schmierer K (2008). High resolution 1H nuclear magnetic resonance spectroscopic-based metabolomic urine analysis of experimental autoimmune encephalitis, a model disease of multiple sclerosis. MULTIPLE SCLEROSIS. vol. 14, S86-S87.
Al-Izki S, Pryce G, Jackson S, Giovannoni G, Baker D (2008). Neuroprotective effects of omega-3 fatty acids in a mouse model of multiple sclerosis. JOURNAL OF NEUROIMMUNOLOGY. vol. 197, 173-173.
Anderson JM, Hampton DW, Patani R, Pryce G, Crowther RA, Reynolds R, Franklin RJM, Giovannoni G et al.(2008). Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. BRAIN vol. 131, 1736-1748.
10.1093/brain/awn119
East E, Gveri¿ D, Baker D, Pryce G, Lijnen HR, Cuzner ML(2008). Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation. Neuropathol Appl Neurobiol vol. 34, (2) 216-230.
10.1111/j.1365-2990.2007.00889.x
Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D(2008). Cannabinoid-mediated neuroprotection, not immuno suppression, may be more relevant to multiple sclerosis. J NEUROIMMUNOL vol. 193, (1-2) 120-129.
10.1016/j.jneuroim.2007.10.024
Pryce G, Jackson SJ, Baker D(2008). Cannabinoids for the control of multiple sclerosis. Cannabinoids and the Brain,
Baker D, Pryce G(2008). The endocannabinoid system and multiple sclerosis. Curr Pharm Des vol. 14, (23) 2326-2336.
10.2174/138161208785740036
Baker D, Jackson SJ, Pryce G(2007). Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol vol. 152, (5) 649-654.
10.1038/sj.bjp.0707458
Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng XD et al.(2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. NAT MED vol. 13, (4) 492-497.
10.1038/nm1561
Pryce G, Baker D(2007). Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. BRIT J PHARMACOL vol. 150, (4) 519-525.
10.1038/sj.bjp.0707003
Baker D, Croxford JL, Pryce G, Jackson SM, Ledent C, Marsicano G, Lutz B, Giovannoni G et al. (2006). Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitis. JOURNAL OF NEUROIMMUNOLOGY. vol. 178, 90-91.
Cabranes A, Pryce G, Baker D, Fernandez-Ruiz J(2006). Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. BRAIN RES vol. 1107, 199-205.
10.1016/j.brainres.2006.06.001
Bilsland LG, Dick JRT, Pryce G, Petrosino S, Di Marzo V, Baker D, Greensmith L(2006). Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J vol. 20, (7) 1003-+.
10.1096/fj.05-4743fje
Baker D, Pryce G, Croxford JL, Yamamura T (2006). Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitits. CURRENT TOPICS IN NEUROIMMUNOLOGY. Editors: Tabira, T, Yamamura, T, Kira, J, 109-116.
Cristino L, De Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V(2006). Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. NEUROSCIENCE vol. 139, (4) 1405-1415.
10.1016/j.neuroscience.2006.02.074
Baker D, Pryce G, Davies WL, Hiley CR(2006). In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci vol. 27, (1) 1-4.
10.1016/j.tips.2005.11.003
Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, Saha B, Mahadevan A et al.(2006). New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. BRIT J PHARMACOL vol. 147, (1) 83-91.
10.1038/sj.bjp.0706418
de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Cabranes A, Pryce G, Baker D, Lopez-Rodriguez M, Ramos JA(2006). UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. EUR NEUROPSYCHOPHARM vol. 16, (1) 7-18.
10.1016/j.euroneuro.2005.06.001
Heijmans N, Smith PA, Morris-Downes MM, Pryce G, Baker D, Donaldson AVJ, 't Hart B, Amor S(2005). Encephalitogenic and tolerogenic potential of altered peptide ligands of MOG and PLP in Biozzi ABH mice. J NEUROIMMUNOL vol. 167, (1-2) 23-33.
10.1016/j.jneuroim.2005.06.005
East E, Baker D, Pryce G, Lijnen HR, Cuzner ML, Gveri¿ D(2005). A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am J Pathol vol. 167, (2) 545-554.
10.1016/S0002-9440(10)62996-3
Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, Giovannoni G, Baker D(2005). Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J NEUROIMMUNOL vol. 165, (1-2) 41-52.
10.1016/j.jneuroim.2005.04.009
Smith PA, Morris-Downes M, Heijmans N, Pryce G, Arter E, O'Neill JK, 't Hart B, Baker D et al.(2005). Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH mice. J NEUROIMMUNOL vol. 164, (1-2) 76-84.
10.1016/j.jneuroim.2005.04.006
Jackson SJ, Diemel LT, Pryce G, Baker D (2005). Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci. vol. 233, 21-25.
10.1016/j.jns.2005.03.002
Pryce G, Baker D(2005). Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci vol. 28, (5) 272-276.
10.1016/j.tins.2005.03.006
Gegg ME, Harry R, Hankey D, Zambarakji H, Pryce G, Baker D, Adamson P, Calder V et al.(2005). Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J IMMUNOL vol. 174, (4) 2327-2335.
10.4049/jimmunol.174.4.2327
Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D(2005). Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience vol. 134, (1) 261-268.
10.1016/j.neuroscience.2005.02.045
Pryce G, Jackson SM, Hankey DRJ, Giovannoni G, Baker D (2004). Cannabinoids are neuroprotective: dissociation of true neuroprotection from protection secondary to immunosuppression. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 78-78.
Pryce G, O'Neill JK, Hankey DRJ, East E, Amor S, Giovannoni G, Baker B (2004). Immunological tolerance that eliminates relapses, fails to halt secondary progression in a chronic multiple sclerosis model. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 62-62.
Baker D, Pryce G(2004). The potential role of the endocannabinoid system in the control of multiple scleorsis. Current Medicinal Chemistry - Central Nervous System Agents vol. 4, (3) 195-202.
10.2174/1568015043356977
East E, Baker D, Pryce G, Cuzner ML, Gveric D (2004). The role of plasminogen activators in experimental allergic encephalomyelitis: inflammation and axonal pathology. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 167-167.
de Lago E, Ligresti A, Ortar G, Morera E, Cabranes A, Pryce G, Bifulco M, Baker D et al.(2004). In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. EUR J PHARMACOL vol. 484, (2-3) 249-257.
10.1016/j.ejphar.2003.11.027
Wilkinson JD, Whalley BJ, Baker D, Pryce G, Constanti A, Gibbons S, Williamson EM(2003). Medicinal cannabis: is Delta(9)-tetrahydrocannabinol necessary for all its effects?. J PHARM PHARMACOL vol. 55, (12) 1687-1694.
10.1211/0022357022304
Pryce G, Ahmed Z, Hankey DJR, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A et al.(2003). Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. BRAIN vol. 126, 2191-2202.
10.1093/brain/awg224
East E, Baker D, Pryce GM, Cuzner ML, Gveric D (2003). The role of plasminogen activators in experimental allergic encephalomyelitis. GLIA. 40-40.
Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P(2003). Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J vol. 17, (8) 905-907.
10.1096/fj.02-1014fje
Pryce G, Giovannoni G, Baker D(2003). Mifepristone or inhibition of 11 beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice. NEUROSCI LETT vol. 341, (2) 164-166.
10.1016/S0304-3940(03)00159-9
Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G(2003). Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol vol. 138, (1-2) 45-48.
10.1016/S0165-5728(03)00092-4
Baker D, Pryce G, Giovannoni G, Thompson AJ(2003). The therapeutic potential of cannabis. LANCET NEUROL vol. 2, (5) 291-298.
10.1016/S1474-4422(03)00381-8
Baker D, Pryce G(2003). The therapeutic potential of cannabis in multiple sclerosis. Expert Opin Investig Drugs vol. 12, (4) 561-567.
10.1517/13543784.12.4.561
Ahmed Z, Doward AI, Pryce G, Taylor DL, Pocock JM, Leonard JP, Baker D, Cuzner ML(2002). A role for caspase-1 and-3 in the pathology of experimental allergic encephalomyelitis - Inflammation versus degeneration. AM J PATHOL vol. 161, (5) 1577-1586.
10.1016/S0002-9440(10)64436-7
Walters CE, Pryce G, Hankey DJR, Sebti SM, Hamilton AD, Baker D, Greenwood J, Adamson P(2002). Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. J IMMUNOL vol. 168, (8) 4087-4094.
10.4049/jimmunol.168.8.4087
Brooks JW, Pryce G, Bisogno T, Jaggar SI, Hankey DJR, Brown P, Bridges D, Ledent C et al.(2002). Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors. EUR J PHARMACOL vol. 439, (1-3) 83-92.
10.1016/s0014-2999(02)01369-9
Ahmed Z, Gveric D, Pryce G, Baker D, Leonard JP, Cuzner ML, Diemel LT(2001). Myelin/axonal pathology in interleukin-12 induced serial relapses of experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol vol. 158, (6) 2127-2138.
10.1016/s0002-9440(10)64684-6
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L et al.(2001). Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J vol. 15, (2) 300-302.
10.1096/fj.00-0399fje
BAKER D. Big conductance calcium-activated potassium channel openers control spasticity without sedation. British Journal of Pharmacology
10.1111/bph.13889
https://qmro.qmul.ac.uk/xmlui/handle/123456789/53704
MEIER U. Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. Multiple Sclerosis and Related Disorders vol. 14, 46-50.
10.1016/j.msard.2017.03.013
https://qmro.qmul.ac.uk/xmlui/handle/123456789/22408
Return to top